Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
Van Oekelen O. et al, (2024), Cell Rep Med
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.
Agarwal G. et al, (2024), Haematologica
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.
Twumasi C. et al, (2023), Eur J Haematol
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K. et al, (2023), Blood Cancer J, 13
Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies.
Khan AO. et al, (2023), Cancer Discov, 13, 364 - 385
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K. et al, (2023), Blood Cancer J, 13
Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.
Agarwal G. et al, (2022), Cancers (Basel), 15
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S. et al, (2022), Blood, 140, 1816 - 1821
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Ansari-Pour N. et al, (2022), Blood
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha P. et al, (2022), Clin Cancer Res, 28, 2854 - 2864
Proceedings from the BMT CTN Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Holstein SA. et al, (2022), Transplant Cell Ther
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response.
Ramasamy K. et al, (2022), Br J Haematol
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.
Karagoz K. et al, (2022), Frontiers in genetics, 13
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma.
Chen LY. and Gooding S., (2022), Front Oncol, 12
COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma.
Ramasamy K. et al, (2021), Br J Haematol
Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK).
Sharpley FA. et al, (2021), Br J Haematol, 192, e136 - e139
Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: Challenges and measurable outcomes.
Djebbari F. et al, (2020), Eur J Haematol, 105, 662 - 666
Gremlin 1 - small protein, big impact: the multiorgan consequences of disrupted BMP antagonism†.
Gooding S. and Leedham SJ., (2020), J Pathol